Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSH | P09668 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | GRPR | P30550 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766784 | 0.89 | ERAP2 (0.37) | ERAP2ERAP1LNPEPCTSLPTPN1 | |
| SCHEMBL21766737 | 0.88 | MAGI3 (0.39) | ERAP2ERAP1LNPEPCTSLPTPN1 | |
| SCHEMBL29517172 | 0.88 | ERAP2 (0.35) | ERAP2ERAP1LNPEP | |
| SCHEMBL31612224 | 0.88 | BACE1 (0.43) | CTSCBACE1BACE2 | |
| SCHEMBL31746072 | 0.85 | PTPN1 (0.49) | ERAP2ERAP1LNPEPCTSLPTPN1 | |
| SCHEMBL29790226 | 0.85 | ERAP2 (0.39) | ERAP2ERAP1LNPEPPTPN1BACE1 | |
| SCHEMBL30997475 | 0.85 | F2 (0.41) | BACE1 | |
| SCHEMBL20230288 | 0.84 | MMP8 (0.40) | ERAP2ERAP1LNPEPCTSLPTPN1 | |
| SCHEMBL23314229 | 0.84 | ERBB2 (0.40) | CTSLPTPN1BACE1CTSSCTSK | |
| SCHEMBL21766780 | 0.84 | BACE1 (0.42) | CTSLPTPN1BACE1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | AVELAS ACQUISITION CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | ERAP2 3586/4885ERAP1 3822/4885LNPEP 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.